Company Overview and News
Under Armour Inc. (NYSE:UAA) is up for the year and has some backing on Wall Street, but Under Armour stock is not all the way back by any means.
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its treatment of major depressive disorder (MDD). The acceptance comes after the FDA had initially issued a "refusal to file" letter for the MDD treatment, ALKS 5461, on March 30. The stock had plunged 22% on April 2, when the news of the letter was released.
CNBC's Jim Cramer has accepted the fact that issues in Washington can indeed weigh on Wall Street, especially going into the weekend.
With high-profile breaches rocking companies like Under Armour and Boeing, the cybersecurity business is not slowing down anytime soon, CNBC's Jim Cramer said on Friday.
With China apparently ready to make significant concessions to the U.S. on trade, it’s definitely worth asking what stocks are likely to benefit from a comprehensive trade deal between the two countries.
The stock market fumbled in the first quarter of 2018. Dragged down by inflation concerns, trade war fears, and technology growth risks, the S&P 500 posted its first quarterly decline since the third quarter of 2015.
Wall Street is growing less confident in the technology sector and continues to be negative on retailers, according to the latest data on short selling.
It’s no secret that stocks are oversold right now, punished by weeks of negative headlines surrounding China-U.S. trade relations, the specter of additional policy tightening by the Federal Reserve, political machinations between President Donald Trump and the ongoing Special Counsel investigation and the possibility that first-quarter earnings expectations are too hot.
Over the past several years, I have closely followed the whole athletic retail competition between Nike Inc (NYSE:NKE), ADIDAS AG/S ADR (OTCMKTS:ADDYY), Under Armour Inc (NYSE:UAA), Skechers USA Inc (NYSE:SKX), and Lululemon Athletica inc. (NASDAQ:LULU).
DICK'S Sporting Goods Inc.’s (DKS - Free Report) growth endeavor of strengthening store network and expanding e-commerce business is commendable. In a move to widen its footprint in Texas and Arkansas, the company has announced the launch of two flagship stores in April. With the accretion of these stores, the company will operate 727 DICK'S Sporting Goods stores across 47 states. As of Feb 3, 2018, the company operated 716 DICK'S Sporting Goods stores across 47 states, 94 Golf specialty stores in 32 states and 35 Field & Stream stores in 16 states.
A patent recently filed by Apple seeks to use advanced sensors on a newly designed Apple Watch band to evaluate sports performance when using third-party equipment, such as golf clubs, baseball bats, footballs or barbells.
I estimate FY18 cash flow from operations to be at least $46M, which would mean a current (EV / Cash flow) ratio of 10 at current valuation.
Once the hottest story in athletic retail, Under Armour Inc (NYSE:UAA) has morphed into the coldest story in athletic retail. Under Armour stock soared from $13 in early 2013 to $50 my mid-2015 as a convergence of tailwinds led to operational momentum which had investors believing that Under Armour could become the next Nike Inc (NYSE:NKE).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _ )* Under Armour, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 904311107 (CUSIP Number)
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET